Close Menu

NEW YORK (GenomeWeb) – Editas Medicine will offer 5.9 million shares of common stock in its planned initial public offering, at a price of $16 per share, according to a document filed today with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based firm said it expects to raise $94.4 million — $87.8 million in proceeds after discounts and commissions to the underwriters.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.